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Summary
 
Viral infections induce CD8 T cell expansion and interferon (IFN)-
 
g
 
 production for defense,
but the innate cytokines shaping these responses have not been identified. Although interleukin
(IL)-12 has the potential to contribute, IL-12–dependent T cell IFN-
 
g
 
 has not been detected
during viral infections. Moreover, certain viruses fail to induce IL-12, and elicit high levels of
IFN-
 
a
 
/
 
b
 
 to negatively regulate it. The endogenous factors promoting virus-induced T cell
IFN-
 
g
 
 production were defined in studies evaluating CD8 T cell responses during lymphocytic
choriomeningitis virus infections of mice. Two divergent supporting pathways were character-
ized. Under normal conditions of infections, the CD8 T cell IFN-
 
g
 
 response was dependent
on endogenous IFN-
 
a
 
/
 
b
 
 effects, but was IL-12 independent. In contrast, in the absence of
IFN-
 
a
 
/
 
b
 
 functions, an IL-12 response was revealed and substituted an alternative pathway to
IFN-
 
g
 
. IFN-
 
a
 
/
 
b
 
–mediated effects resulted in enhanced, but the alternative pathway also pro-
moted, resistance to infection. These observations define uniquely important IFN-
 
a
 
/
 
b
 
–con-
trolled pathways shaping T cell responses during viral infections, and demonstrate plasticity of
immune responses in accessing divergent innate mechanisms to achieve similar ultimate goals.
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I
 
mmune responses to various classes of infectious agents
have many overlapping, but certain unique or uniquely
dominant, characteristics (1). The elements appear to be in
place to access and/or deliver mechanisms most effective in
defense against the eliciting infectious organism. Innate cyto-
kine responses can have roles in shaping downstream adap-
tive, as well as other innate, immune responses (2). The par-
adigm emerging from bacterial and parasite studies has
IL-12 as the pivotal innate cytokine for promoting NK and
T helper type 1 (Th1) cell IFN-
 
g
 
 responses (3–9). Roles
for this cytokine in immune responses to viruses are less
clear. Biologically active IL-12 is not induced during all
viral infections (10–13). The cytokine is part of the innate
immune response and stimulates NK cell IFN-
 
g
 
 produc-
tion during murine cytomegalovirus (MCMV)
 
1
 
 (10, 11)
and influenza virus (12), but not lymphocytic choriomen-
ingitis virus (LCMV) (11), infections of mice. Moreover,
IL-12–dependent T cell IFN-
 
g
 
 responses are not demon-
strable in number of viral infections including those that do
or do not induce detectable IL-12 (11, 12, 14).
In contrast to infections with other agents, many viruses
elicit high levels of the innate cytokines, type 1 interferons
(i.e., IFN-
 
a
 
/
 
b
 
) and adaptive CD8 T cell responses. During
LCMV infections lacking detectable IL-12, early and dra-
matic elevations in IFN-
 
a
 
/
 
b
 
 concentrations are induced
on days 2 and 3 after infection (10, 11, 13, 15), and T cell
immune responses characterized by profound CD8 T cell
expansion and IFN-
 
g
 
 production are elicited on or after
days 7–9 (16–22). Specificity of the CD8 T cell responses
has been proven by direct visualization with binding of
MHC class I tetramer molecules complexed to LCMV
epitopes (23), and by stimulation of IFN-
 
g
 
 expression with
LCMV peptides (23–25). The innate cytokines important
for promoting these T cell responses have not been de-
fined. IFN-
 
a
 
/
 
b
 
 cytokines can contribute to a variety of
immunoregulatory effects (26), and are reported to pro-
mote T cell IFN-
 
g
 
 production under certain culture con-
 
1
 
Abbreviations used in this paper:
 
 CM, conditioned media; LCMV, lympho-
cytic choriomeningitis virus; MCMV, murine cytomegalovirus; WT,
wild-type. 
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ditions (27–29). Thus, they may be a class of innate cyto-
kines uniquely regulating adaptive T cell responses to viral
infections.
The studies reported here were undertaken to define
roles for innate cytokines in supporting antiviral T cell re-
sponses. The experiments, carried out during LCMV infec-
tions of mice, demonstrate for the first time the major en-
dogenous innate pathways to CD8 T cell IFN-
 
g
 
 during
viral infections. They show that the IFN-
 
a
 
/
 
b
 
 cytokines are
dominant in promoting conditions for this T cell IFN-
 
g
 
production. Moreover, they demonstrate that although T
cell IFN-
 
g
 
 responses are IL-12 independent in the context
of IFN-
 
a
 
/
 
b
 
 induction and function, IL-12 revealed in the
absence of IFN-
 
a
 
/
 
b
 
 functions can substitute to promote
IFN-
 
g
 
 production. This alternative pathway is beneficial
but not sufficient for induction of optimal protection.
Taken together, the data define unique factors and condi-
tions regulating immune responses to viral infections. Fur-
thermore, they result in the discovery of alternative innate
cytokine pathways for promoting IFN-
 
g
 
 responses.
 
Materials and Methods
 
Mice. 
 
Mice deficient in IL-12, as a result of targeted disrup-
tion of the IL-12p35 gene (IL-12p35 KO), were generated and
bred at Genetics Institute, using the p35 SK
 
1
 
 vector (Stratagene
Inc.), the embryonic stem cell system in 129/sv mice, and estab-
lished procedures (30–32). Mice were backcrossed onto the
C57BL/6 genetic background for two to four generations. Homo-
zygous mutant (
 
2
 
/
 
2
 
 or KO) and homozygous wild-type (WT)
IL-12p35 gene mice were taken from littermates for use in these
studies. The gene targeting vector eliminated exons 1–4 by re-
placement with the neomycin resistance gene (see Fig. 1 A). Dis-
ruption of the p35 gene was demonstrated by Southern blot anal-
ysis (see Fig. 1 B). Functional deletion of IL-12 was confirmed by
absence of IL-12p70 heterodimers after challenge with the known
stimulators lipopolysaccharide treatment and MCMV infection.
For these studies, mice were injected at 0 h with 500 
 
m
 
g/kg LPS
(3), and blood collected for serum sample preparation at 2.5 and
5 h (see Fig. 1 C), or infected with 5 
 
3 
 
10
 
4
 
 PFU of Smith strain
MCMV V70 salivary gland extract, and blood collected for serum
sample preparation at 36 h (Fig. 1 D). Lack of IL-12 was shown to
have biological consequences because the IL-12–dependent induc-
tion of natural killer cell IFN-
 
g
 
 production after MCMV infection
was blocked in the IL-12p35 KO compared with WT mice (see
Fig. 1 D).
Mice deficient in IFN-
 
a
 
/
 
b
 
 receptor function as a result of ge-
netic mutation (IFN-
 
a
 
/
 
b
 
R KO) on the 129/Sv background (33,
34), originally obtained from B&K Universal Limited, were bred
and maintained in strict isolation in the animal facility at Brown
University. Age-matched WT 129 control (129 SvEvTacFBR)
mice were purchased from Taconic Farms Inc. All mice used in
experiments had the H-2
 
b
 
 major histocompatibility complex and
were handled in accordance with institutional guidelines for ani-
mal care and use.
 
Treatments.
 
The LCMV infections were established i.p. on
day 0 with 2 
 
3 
 
10
 
4
 
 PFU of Armstrong strain, clone E350 (11, 13,
35, 36). CD8 T cells were depleted in vivo by treatment i.p. with
0.5 mg of monoclonal anti–CD8 antibody 2.43, prepared from
ascites, on day 5 after infection. Control treatment was with par-
tially purified P3NS1 ascites containing 0.5 mg rat IgG (Sigma
 
Chemical Co.). Sheep antimurine IFN-
 
a
 
/
 
b
 
 IgG was injected
(0.15 mg/mouse) to neutralize IFN-
 
a
 
/
 
b
 
 with nonspecific sheep
IgG used as control antibody (gifts of Ion Gresser, Center Na-
tional de la Recherche Scientifique, Villejuif, France) (10, 13, 37,
38). The rat IgG monoclonal directed against the mouse IL-12
p40 chain, C17.8, was used to neutralize IL-12 function in vivo.
Partially purified ascites preparations (1 mg) were injected to neu-
tralize IL-12 with rat IgG added to P3NS1 ascites used as control
antibody (10, 11). Injections were i.p. 14 h before, and day 4 of,
LCMV infections. Splenic leukocytes were isolated from macer-
ated whole spleens after passage through nylon mesh and osmotic
lysis of erythrocytes by ammonium chloride treatment, with via-
ble cell yields determined by trypan blue exclusion.
 
Cytokine Analyses. 
 
Samples for quantitation of IFN-
 
g 
 
and
IL-12 p70 were prepared as reported previously (11, 13, 17).
Conditioned media (CM) were generated by incubating 10
 
7
 
splenic leukocytes/ml in 10% FBS-RPMI 1640 media for 24 h at
37
 
8
 
C before harvest of culture supernatants. Where indicated,
CM samples were prepared by incubation of splenic leukocytes
with or without 0.1 
 
m
 
g/ml LCMV peptides NP396-404 or
GP33-41 in 48-well flat-bottom plates at concentrations of 2 
 
3
 
10
 
6
 
 cells per well in 0.4 ml of 10% FBS-RPMI supplemented with
50 U/ml human recombinant IL-2 (23, 25, 39). IFN-
 
g
 
 was mea-
sured by sandwich ELISA (11, 13, 17). Standard curves of mrIFN-
 
g
 
(PharMingen) indicated detection limits of 10–40 pg/ml in serum,
or 1–4 pg/10
 
6
 
 cells in CM. IL-12 p70 was quantitated either in an
ELISA (Genzyme Corp.) or in a biological assay (11, 13). Limit of
detection for IL-12 p70 in the biological assay was 0.7 pg/ml
serum. IL-2 was quantitated in ELISA using reagents from Phar-
Mingen according to the manufacturer’s recommendations.
 
Flow Cytometric Analysis. 
 
As per modification of published
techniques (40), cells were stimulated on 24-well cluster plates
previously coated overnight with 0.5 ml 10 
 
m
 
g/ml purified ham-
ster anti–mouse CD3
 
e
 
 mAb 145-2C11 (PharMingen) in PBS.
Plates were washed with PBS, and 2 
 
3 
 
10
 
6
 
 cells in 2 ml 10%
FBS-RPMI per well were incubated for a total of 6 h, with
Brefeldin A (Sigma Chemical Co.) added the last 2 h. Alterna-
tively, splenic leukocytes were stimulated with 0.1 
 
m
 
g/ml of the
LCMV peptides NP396-404 or GP33-41 (23). Cells for these ex-
periments were incubated in 48-well flat-bottom plates at con-
centrations of 2 
 
3 
 
10
 
6
 
 cells per well in 0.4 ml of 10% FBS-RPMI
supplemented with 50 U/ml human recombinant IL-2, at 37
 
8
 
C
for 5 h total, with Brefeldin A added for the last 3 h. After stimu-
lation, cells were washed in staining buffer (0.5% BSA and
0.006% NaN
 
3
 
 in PBS), incubated for 30 min at 4
 
8
 
C with bioti-
nylated rat anti–CD4 mAb clone RM4-5 (PharMingen), washed
twice with staining buffer, incubated 30 min at 4
 
8
 
C with strepta-
vidin-PerCP (Becton Dickinson & Co.) and anti–CD8
 
a
 
 FITC-
conjugated rat mAb 53-6.7 (PharMingen), washed once with
staining buffer, once with PBS, resuspended at 10
 
6
 
 cells/ml, and
fixed with an equal volume of 4% formaldehyde in PBS for 20
min at room temperature. For cytoplasmic staining, cells were
washed once with PBS, once with staining buffer, treated with
150 
 
m
 
l of permeabilization buffer (1% saponin in staining buffer;
Sigma Chemical Co.), resuspended in 25 
 
m
 
l permeabilization
buffer containing 300 
 
m
 
g/ml rat IgG (Sigma Chemical Co.), in-
cubated 10 min at room temperature, and incubated for 20 min
at room temperature with anti–IFN-
 
g
 
 PE-conjugated rat mAb
XMG1.2 (PharMingen). Specificity of IFN-
 
g
 
 staining was estab-
lished by preincubation of anti–IFN-
 
g
 
-PE with recombinant
murine IFN-
 
g
 
 at 0.25 mg/test, before incubation with cells
(cold block), or preincubation of cells with excess unconjugated
XMG1.2 (cold competitor), and nonspecific staining assessed by use 
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of control antibodies lacking specificities for murine determinants
(PharMingen). Cells were washed twice with permeabilization
buffer, once with staining buffer, and acquired immediately. H2D
 
b
 
tetramers, containing LCMV peptides NP396-404, GP33-41, and
GP276-286, prepared, and conjugated with allophycocyanin as de-
scribed, were used for surface staining along with anti–CD8 PE-
conjugated rat mAb 52-6.7 (PharMingen) (23, 41). After incuba-
tion of 10
 
6
 
 cells with tetramer for 1 h, cells were washed two times
in 13 PBS supplemented with 2% FBS, fixed with 4% paraformal-
dehyde and washed one time. All samples were acquired at Brown
University on a FACSCalibur® (Becton Dickinson & Co.), using
CELLQUEST 3.0 software. More than 20,000 events were col-
lected, with laser outputs of 15 mW at 488 or 635 nM.
Viral Plaque Assays. Livers and spleens were frozen at
2808C, thawed, homogenized, and LCMV titers were mea-
sured by plaque formation on Vero cells as previously described
(17, 35, 36).
Results
Requirements for Endogenous IL-12 Function.  To conclu-
sively exclude a role for IL-12 in T cell responses to LCMV
infection, mice were made deficient for the p35 subunit of
IL-12 (IL-12p35 KO) by homologous recombination with
a deleted gene construct, as described in Materials and
Methods and Fig. 1. None of the day 8 splenic T cell re-
sponses to LCMV infection were significantly reduced in
the IL-12p35 KO mice. Yield and flow cytometric analyses
demonstrated that overall expansion of CD8 T cells was
Figure 1. Development and testing of IL-12p35 KO mice. (A) Strategy for targeted disruption of the IL-12p35 locus is given. The IL-12p35 genomic
structure is represented; closed boxes indicate location of the coding regions, which are numbered beneath, and white boxes indicate noncoding regions.
The IL-12p35 targeting vector was constructed in the pBS SK1 vector and engineered by replacing a 5-kb HindIII-XbaI fragment containing exons 1–4
with a 1.6-kb neomycin resistance gene, represented as a striped box, under control of the PGK promoter. A 2.3-kb thymidine kinase cassette, repre-
sented as a stippled box, also under the control of the MC1 promoter, was inserted immediately adjacent to the 39 end of the IL-12p35 genomic flanking
sequence. A 1-kb Kpn1-XbaI fragment located downstream of exon 7, used as a probe for genomic Southern blot analysis, is indicated by a closed bar
beneath. The size and location of fragments predicted for wild-type and mutant alleles expected during Southern analysis are indicated by double-headed
arrows. The targeting construct was linearized at the pBS NotI site and electroporated into J1 embryonic stem cells grown and cultured under G418 and
Gancyclovir selection. Restriction enzyme sites are indicated as follows: N, NeoI; H, HindIII; B, BamHI; X, XbaI; V, EcoRV; and K, KpnI. (B) Mouse
genotyping using genomic Southern analysis. Genomic DNA was extracted from tail fragments of IL-12p35 1/1, IL-12p35 1/2, and IL-12p35 2/2
mice. After BamHI/EcoRV restriction digestion, DNA was fractionated on 0.8% agarose gel, blotted onto membranes, and hybridized with 32P-labeled
probe. (C) LPS induction of IL-12p70 expression. IL-12p35 1/1 and IL-12p35 2/2 mice were injected with 500 mg/kg LPS. Blood was collected for
serum sample preparation at 2.5 and 5 h after LPS injections. IL-12p70 was detected in an ELISA. Results are representative of two identical experiments
containing six mice per group and are shown as means 6 SEM. (D) MCMV induction of IL-12p70 and IFN-g expression. IL-12p35 1/1 and IL-12p35
2/2 mice were either uninfected or infected with 5 3 104 PFU of Smith strain MCMV for 36 h and serum was prepared. IL-12p70 was measured by
antibody capture and use in a biological assay. IFN-g was measured in an ELISA. Results represent experiments containing three mice per group and are
shown as means 6 SEM.1318 IFN-a/b and IL-12 Pathways for Antiviral T Cell Responses
similar in both WT and IL-12p35 KO (Fig. 2 A). Further-
more, ELISA studies demonstrated that induction of IFN-g
expression, both in media conditioned with splenic leuko-
cytes (CM) and in serum, was neither blocked nor signifi-
cantly inhibited in the absence of IL-12 (Fig. 2 B). Because
CD8 T cells are the predominant IFN-g producers during
LCMV infection, IFN-g expression by CD8 T cells also
was measured by flow cytometric analysis for cytoplasmic
protein and shown to be unaffected by absence of IL-12.
Upon stimulation ex vivo with immobilized anti–CD3,
z60–70% of the cells induced to express cytoplasmic IFN-g
from both types of mice were CD8 T cells, and the pro-
portions of IFN-g–expressing CD8 T cells were 43.2% (6
8.0) and 43.5% (6 4.7) (means 6 SEM) in WT and IL-
12p35 KO mice, respectively (Fig. 2 C). Likewise, total
numbers of CD8 T cells expressing IFN-g, calculated
based on CD8 T cell yields, were equivalent with 7.9 (6 2.2)
and 9.6 (6 2.7) 3 106 cells (Fig. 2 C). The endogenous re-
sponses were sufficient to mediate protection against infec-
tion because viral titers were below detectable levels in
both infected WT and IL-12p35 KO mice by day 8 (data
not shown). Thus, T cell proliferation and IFN-g produc-
tion occur in the complete absence of the biologically ac-
tive IL-12 heterodimer during infections with this virus,
and the immune responses induced under these conditions
are protective.
Requirements for Endogenous IFN-a/b Functions. Exper-
iments were carried out to characterize roles of IFN-a/b
in regulating the T cell responses. Although of lower mag-
nitude on the inbred genetic 129 background of these
Figure 2. T cell responses in mice lacking endogenous sources of either IL-12 or IFN-a/b. Mice, WT and IL-12p35 KO 129/B6 (A–C) or WT and
IFN-a/bR KO 129 (D–F), were either uninfected (open bars or symbols) or infected i.p. (closed bars or symbols) on day 0 with 2 3 104 PFU LCMV
Armstrong strain. On day 8 after infection, blood and spleens were harvested and processed. Total numbers of CD8 T cell splenic leukocytes were calcu-
lated by multiplying the percentages of CD8 cells, determined by flow cytometry, with the total cell yields (A and D). IFN-g levels were measured, in
media conditioned with splenic leukocytes and in serum samples, by ELISA (B and E). For flow cytometric analysis of cytoplasmic IFN-g expression,
splenic leukocytes were stimulated for 6 h with anti–CD3, with Brefeldin A during the last 2 h. Cells were collected and stained for cell surface expres-
sion of CD8, CD4, and cytoplasmic expression of IFN-g (C and F). Histogram plots were formed by gating on the CD8 population, and displaying CD8
T cell number versus IFN-g fluorescence intensity. Numbers of CD8 T cells expressing IFN-g were calculated by multiplying the percentage of CD8 T
cells expressing IFN-g by the number of CD8 T cells per spleen (3 106), and given as means 6 SEM. Results are representative of two or more repetitive
experiments with two to four mice per uninfected group and three to four mice per infected group. Data are shown as means 6 SEM.1319 Cousens et al.
mice, inductions of CD8 T cell expansion and IFN-g ex-
pression were observed and similar in both WT and IFN-
a/bR KO mice (Fig. 2, D and E). IFN-g levels, measured
in samples from the IFN-a/bR KO mice, were equal to
or greater than those from WT mice in CM and serum
(Fig. 2 E). Interestingly, serum IFN-g levels were en-
hanced significantly by more than threefold in samples ob-
tained from IFN-a/bR KO, as compared with WT, mice.
Studies, in IFN-a/bR KO mice depleted of endogenous
CD8 T cells by antibody treatments, demonstrated that 66%
of the enhanced serum IFN-g was dependent on endog-
enous CD8 T cells. After anti–CD3 stimulation ex vivo,
50–60% of the IFN-g expressing cell types from both IFN-
a/bR KO and WT mice were CD8 T cells (data not shown),
and similar proportions of the CD8 T cell subset from both
types of mice were induced to express the cytokine (Fig. 2
F). As these T cell responses are intact, the data suggest that
IFN-a/b deficiencies by themselves do not result in gener-
alized T cell exhaustion or depletion. However, viral titers
were increased in IFN-a/bR KO relative to WT mice (see
below). Hence, the CD8 T cell expansion and IFN-g pro-
duction are not IFN-a/b dependent, but the conditions
result in decreased resistance to infection.
Because total expansion and IFN-g expression were in-
tact, but levels of virus were increased, antigen specificity
of the responding cells was tested. To enumerate CD8 cells
bearing T cell receptors for LCMV antigens, splenic leuko-
cytes were labeled with anti–CD8 and tetramers of Db
MHC class I molecules containing LCMV peptides immuno-
dominant for CD8 T cell responses (NP396-404 or GP33-
41), as described in Materials and Methods. Flow cytometric
analyses showed significant increases in percentages of CD8
T cells binding tetrameric Db NP396-404 or Db GP33-41
with cells from day 8 LCMV-infected, relative to uninfected,
WT mice (Fig. 3, A and B). Samples from IFN-a/bR KO
mice also had significant increases in proportions of tet-
rameric Db NP396-404– and Db GP33-41–binding CD8 T
cells after infection (Fig. 3, A and B). T cell frequencies spe-
cific for tetramers with NP396-404 were higher in WT,
whereas those with GP33-41 were higher in IFN-a/bR
KO, populations. Total numbers of CD8 T cells binding the
complexed tetramers were significantly increased after in-
fection, relative to uninfected samples, in both WT and
IFN-a/bR KO mice (Fig. 3 C). Moreover, because of in-
creases in average splenic cell yields after infection, the total
numbers of CD8 T cells specific for the tetrameric Db LCMV
Figure 3. Specificity of CD8 T cell expansion
after LCMV infection of IFN-a/bR KO mice.
WT and IFN-a/bR KO mice were uninfected
or were infected i.p. on day 0 with 2 3 104 PFU
LCMV Armstrong strain, and spleens were har-
vested and processed on day 8. CD8 populations
positive for binding Db tetramers complexed with
LCMV peptides NP396-404 (NP396) or GP33-
41 (GP33) were assessed by flow cytometric anal-
ysis. Dot plots (A) of CD8 versus tetramer fluo-
rescence intensity are shown. Circles identify areas
of CD8 T cells binding complexed tetramers.
Numbers given in corners of dot plots indicate
the percent of CD8 T cells that are tetramer posi-
tive for the individual sample. Averages of pro-
portions (B) and numbers (C) of CD8 T cells that
are tetramer positive for uninfected (open bars)
and day 8 LCMV infected (closed bars) shown are
for three mice per group, 6 SEM. Results are
representative of two repetitive experiments. *In-
fected samples are significantly different relative
to uninfected samples, P # 0.05, as determined
by a two-tailed Student’s t test. Broken lines
across graphs in B and C signify basal staining of
cells from uninfected mice.1320 IFN-a/b and IL-12 Pathways for Antiviral T Cell Responses
peptide complexes were higher in the IFN-a/bR KO than
the WT mice, respectively, averaging 247 and 120 3 104
cells per spleen. As a result of their skewed proportional rep-
resentation, however, the Db GP33-41 binding cells respec-
tively comprised z75 and 20% of the populations, and ap-
peared to account for a large proportion of the enhanced
expansion of T cells recognizing viral epitopes in the IFN-
a/bR KO mice. Thus, as in WT mice, expanding CD8 T
cells in IFN-a/bR KO mice are specific for the virus. How-
ever, in the absence of IFN-a/b function, responses are dif-
ferentially elicited to particular LCMV epitopes.
To demonstrate specificity of functional CD8 T cells,
IFN-g expression responses to the LCMV NP396-404 and
GP33-41 peptides were evaluated ex vivo. Cells from un-
infected WT or IFN-a/bR KO mice were not stimulated
by either of these peptides (data not shown). In contrast, on
day 8 after LCMV infection, significant increases in CD8 T
cells expressing cytoplasmic IFN-g, relative to samples pre-
Table I. IFN-a/b Effects on LCMV-specific IFN-g Production on Day 8 after LCMV Infection
Stimulation
IFN-g Production (pg/106 cells)
WT IFN-a/bR KO
Uninfected Day 8 LCMV Uninfected Day 8 LCMV
No peptide ,25 642.7 6 164.3 ,25 461.6 6 97.3
NP396-404 ,25 18,778.1 6 5,776.0 ,25 608.5 6 102.8
GP33-41 ,25 10,108.4 6 4,909.5 ,25 4,437.4 6 723.1
Conditioned media were generated as described in Materials and Methods, using splenic leukocytes from WT or IFN-a/bR KO mice, uninfected
or 8 d after LCMV infection, in the presence or absence of LCMV peptide. IFN-g levels were measured by ELISA. Shown are averages of three
mice per group 6 SEM. Limit of detection for this assay was 25 pg/106 cells.
Figure 4. LCMV epitope-specific
stimulation of CD8 T cell IFN-g ex-
pression in cells from IFN-a/bR KO
mice. WT and IFN-a/bR KO mice
were infected i.p. on day 0 with 2 3 104
PFU LCMV Armstrong strain. On day
8 after infection, spleens were harvested
and processed. Splenic leukocytes were
stimulated in the presence or absence of
the immunodominant LCMV peptides
NP396-404 or GP33-41, or anti–CD3,
and labeled for flow cytometric analysis
of cytoplasmic IFN-g protein in CD8 T
cells, as described in Materials and
Methods. Dot plots (A) display CD8
versus IFN-g fluorescence intensity,
with CD8 T cells expressing IFN-g cir-
cled. Numbers given in corners of dot
plots are proportions of CD8 T cells ex-
pressing cytoplasmic IFN-g for the indi-
vidual samples. Averages of proportions
(B) and numbers (C) of CD8 T cells
positive for IFN-g expression are shown
for three mice per group, 6 SEM. Re-
sults are representative of two repetitive
experiments.1321 Cousens et al.
pared in the absence of exogenous stimulation, were ob-
served after peptide stimulation of either WT or IFN-a/bR
KO splenic leukocytes (Fig. 4). Consistent with the Fig.
2 H experiments, proportions of total primed CD8 T cells
responding to anti–CD3 stimulation for IFN-g expression
remained similar (Fig. 4 B). However, even though the to-
tal proportions of cells specific for binding tetramers with
LCMV peptides (Fig. 3 B), and of cells expressing cytoplas-
mic IFN-g after anti–CD3 stimulation (Fig. 4 B), were
similar, lower proportions of cells from IFN-a/bR KO as
compared with WT mice were stimulated in response to
peptides (Fig. 4 B). Interestingly, despite dramatic increases
in cells binding tetrameric Db GP33-41 (Fig. 3), the pro-
portions and numbers of cells responding to this peptide for
IFN-g expression were similar or only marginally higher in
IFN-a/bR KO compared with WT populations (Fig. 4).
Thus, the reduced IFN-g responses with cells from IFN-
a/bR KO mice appeared to be a consequence of specifically
binding populations failing to detectably respond to GP33-
41 stimulation for IFN-g expression. Evaluation of cyto-
kine in CM demonstrated similar levels of population re-
sponsiveness to the LCMV peptides (Table I). These studies
demonstrate induction of LCMV-specific CD8 T cell IFN-g
production responses in the absence of IFN-a/b functions.
Taken together with the tetramer binding results, they pro-
vide evidence that a proportion of the CD8 T cells speci-
fically expanding in response to viral epitopes are altered
in their requirements for stimulation and/or magnitude of
functional responses.
Cytokine Effects on Viral Burdens.  Kinetic studies of vi-
ral clearance during the experiments reported here, sam-
pling on various days after LCMV infection, demonstrated
that viral burdens in both IL-12p35 KO (data not shown)
and WT mice were below detection by day 8 after infec-
tion. Extended studies of WT and IFN-a/bR KO mice
showed that WT mice had viral burdens that peaked
around day 4.5 at levels of 6.2 (6 0.2) and 5.0 (6 0.2) log
PFU/g of spleen and liver, respectively, and were below
detection by day 7 (Fig. 5). Similar kinetics of splenic and
hepatic viral titers were observed in IFN-a/bR KO mice,
but these peaked at the higher levels of 10.3 (6 0.2) and
10.5 (6 0.0) log PFU/g of respective tissue on day 4.5 after
infection, and declined by day 7 (Fig. 5). Interestingly, de-
creases in splenic and liver viral loads were observed in the
IFN-a/bR KO mice over time to 4.7 (6 0.2) and 4.2 (6
0.0) log PFU/g of tissue, respectively, on day 14 after in-
fection, and below the limits of detection by day 28 after
infection (Fig. 5). Thus, absence of an endogenous IL-12
response does not increase sensitivity to LCMV infection,
and although absence of IFN-a/b functions does, viral
clearance is eventually achieved.
Substitution of an IL-12 Response in the Absence of IFN-a/b.
Because IL-12 expression can be revealed during LCMV
infection by neutralization of endogenous IFN-a/b func-
tions (13), a released IL-12 induction may substitute in sup-
porting T cell responses under these conditions. Measure-
ments of IL-12 p70 in serum demonstrated that the factor
was induced to detectable levels on days 1.5 and 3 of LCMV
infection in IFN-a/bR KO, but not WT, mice (Fig. 6).
Therefore, IL-12 effects on the T cell responses were ex-
amined in IFN-a/bR KO mice by treatments with anti-
bodies neutralizing IL-12. Although anti–IL-12 treatments
did not modify IFN-g production responses as compared
with control antibody treatments in WT mice, they signifi-
cantly reduced IFN-g production on day 8 in LCMV-
infected IFN-a/bR KO mice; relative to cells isolated
from control-treated IFN-a/bR KO mice, 70% decreases in
CM spontaneous production of IFN-g were observed (Fig.
7 A, left). Furthermore, anti–IL-12 treatment of IFN-a/bR
KO mice, resulted in a .85% reduction in CM IFN-g
levels, as compared with anti–IL-12–treated WT mice (Fig.
7 A, left, striped bars); i.e., from 66.4 (6 16.0) to 7.8 (6 2.0)
pg/106 cells. Consistent with the experiments shown in
Figure 5. LCMV viral titers in IFN-a/bR KO as compared with WT
mice. WT (s) and IFN-a/bR KO (d) mice were infected on day 0
with 2 3 104 PFU LCMV Armstrong strain. Spleens and livers were har-
vested on 1.5, 3, 4.5, 7, 8, 9.5, 11, 14, 21, 28, or 35 d after infection, for
quantitation of LCMV titers in plaque assays. Data shown are means for
three mice per group 6 SEM, and the solid lines across the graphs repre-
sent the lower limits of detection.
Figure 6. IL-12 p70 induction during LCMV infections of IFN-a/bR
KO mice. Serum samples taken from WT (open bars) and IFN-a/bR
KO (closed bars) mice that were either uninfected or infected for 1.5, 3,
4.5, 7, 8, or 9.5 d with 2 3 104 PFU LCMV Armstrong strain. A capture
biological assay was used to measure IL-12 p70 levels. Values shown are
means of two to three mice per group, 6 SEM. Solid line across graph
indicates limit of detection for the assay.1322 IFN-a/b and IL-12 Pathways for Antiviral T Cell Responses
Fig. 2, B and E, only low levels of serum IFN-g were de-
tected in WT mice, but were increased by more than
threefold in IFN-a/bR KO mice (Fig. 7 A, right). Given
the contribution of CD8 T cells to serum IFN-g (see above),
the stimulation of CD8 T cell IFN-g expression by LCMV
epitopes (Fig. 4), and the significant increases in viral bur-
dens (Fig. 5, day 8), elevated in vivo stimulation of the
CD8 T cells by LCMV epitopes was likely to have contrib-
uted to higher serum IFN-g levels in the IFN-a/bR KO
mice. IL-12 also participated in this enhanced response be-
cause neutralization of the factor resulted in a 40% reduc-
tion in serum IFN-g levels (Fig. 7 A, right). Thus, in the
absence of endogenous IFN-a/b effects during a viral in-
fection, IL-12 can be induced and substitute to provide
conditions supporting IFN-g responses.
To confirm and extend these studies, IFN-a/b effects
were examined under the reciprocal conditions in mice
lacking endogenous IL-12. For these experiments, WT and
IL-12p35 KO mice were treated with antibodies neutraliz-
ing IFN-a/b or control antibodies. Cytokine neutralization
of WT mice resulted in IFN-g responses comparable with
those in IFN-a/bR KO mice; i.e., IFN-g production in
CM was not blocked and was induced to elevated levels in
serum (Fig. 7 B). Relative to control-treated mice, antibody-
mediated neutralization of IFN-a/b in IL-12p35 KO mice
significantly inhibited IFN-g levels spontaneously produced
in CM (Fig. 7 B, left). Moreover, in comparison with anti–
IFN-a/b–treated WT mice, serum IFN-g levels were re-
duced by .90% as a result of IFN-a/b neutralization in the
IL-12p35 KO mice; i.e., whereas the anti–IFN-a/b–
treated WT mice had levels of 1,454.2 (6 171.2) pg/ml in
serum, the anti–IFN-a/b–treated IL-12p35 KO mice had
only 110.9 (6 30.6) (Fig. 7 B, right, striped bars). Thus, in
the absence of endogenous IL-12, IFN-a/b–mediated ef-
fects are primarily responsible for endogenous conditions
promoting the IFN-g responses to viral infections.
To evaluate the specificity of CD8 T cell responses for
LCMV, under the conditions of anti–IL-12 treatment in
IFN-a/bR KO mice, experiments were carried out examin-
ing peptide or anti–CD3 stimulation for cytoplasmic IFN-g
expression, specific stimulation by peptides for IFN-g pro-
duction in CM, and surface binding of tetramers com-
plexed with peptides immunodominant for CD8 T cells.
Overall, both the control and anti–IL-12 antibody treat-
ments modestly blunted magnitudes of the ex vivo–
detected specific responses. As a result, intracytoplasmic la-
Figure 7. T cell responses in mice lacking endogenous function of both IL-12 and IFN-a/b. Mice, WT and IFN-a/bR KO 129 (A) or WT and IL-
12p35 KO 129/B6 (B), were infected i.p. on day 0 with 2 3 104 PFU LCMV Armstrong strain. The WT and IFN-a/bR KO 129 mice received either
control or neutralizing C17.8 anti–IL-12p40 antibodies. The WT and IL-12p35 KO 129/B6 mice received either control or polyclonal neutralizing
anti–IFN-a/b antibodies. All antibody treatments were given i.p. on days 21 and 4 relative to infection. On day 8 after infection, blood and spleens
were harvested and processed. Levels of IFN-g in splenic leukocyte CM and serum samples were measured by ELISA. Hatched bars represent samples
from mice with antibody-mediated neutralization of cytokine functions. Data shown are means 6 SEM. Significantly different P values were calculated
by a two-tailed Student’s t test comparing either anticytokine- to control-treated mutant mice (*,**) or anticytokine-treated mutant to wild-type mice
(11), *P # 0.05, **P # 0.01, 11P # 0.01. As a result of pooling results from two repetitive experiments, the values in A represent mean results with
six mice per group. Those in B represent means of results from three mice per group.
Figure 8. LCMV-specific IFN-g
production in mice lacking endoge-
nous IFN-a/b function. IFN-a/bR
KO mice were infected i.p. on day 0
with 2 3 104 PFU LCMV Arm-
strong strain. They received either
control (closed bars) or C17.8 anti–
IL-12 (striped bars) antibodies, given
i.p. on days 21 and 4 relative to in-
fection. On day 8 after infection,
spleens were harvested and pro-
cessed to generate CM in the pres-
ence or absence of the immuno-
dominant LCMV peptides NP396-404 (NP396) or GP33-41 (GP33).
Levels of IFN-g in samples were measured by ELISA. Data presented are
means for three mice per group 6 SEM. Significantly different (*) P val-
ues comparing anti–IL-12– to control-treated IFN-a/bR KO mice were
calculated by a two-tailed Student’s t test and were #0.05.1323 Cousens et al.
beling was not sensitive enough to identify changes in the
low proportions of CD8 T cells specifically responding to
peptides with cytoplasmic IFN-g expression (see Fig. 4).
However, it was possible to demonstrate decreases, result-
ing from the blocking IL-12 function in IFN-a/bR KO
mice, in the proportion of CD8 T cells primed for anti–
CD3 stimulation of IFN-g expression; i.e., 18.3% (6 2.2)
to 12.8% (6 0.2). The anti–IL-12 treatments also resulted
in significant 46 and 53% inhibitions of NP396-404– and
GP33-41–stimulated IFN-g production, respectively, in
CM (Fig. 8). In contrast to the effects on IFN-g responses,
blocking of both cytokine pathways did not inhibit LCMV-
induced CD8 T cell expansion; increased proportions and
numbers of CD8 T cells specific for Db NP396-404 and Db
GP33-41 were observed with or without IL-12 neutraliza-
tion (data not shown). These studies demonstrate that the
conditions of a revealed IL-12 pathway, in the absence of
IFN-a/b–mediated functions, result in IFN-g production
promoted in a virus-specific manner by epitopes immu-
nodominant for CD8 T cell responses. In contrast, the re-
sults indicate that specific CD8 T cell proliferation can oc-
cur in the absence of both IL-12 and IFN-a/b–mediated
effects.
Antiviral Effect of Substituted IL-12 Response. To assess the
contribution of IL-12 to virus clearance in the absence of
IFN-a/b function, viral titers were measured in LCMV-
infected mice having had both factors blocked. Anti–IL-12
treatment of IFN-a/bR KO mice resulted in statistically
significant (P , 0.01) increases in viral titers of almost 1 log
by day 14 after infection; spleens and livers from anti–IL-
12–treated IFN-a/bR KO had 5.8 (6 0.0) and 5.3 (6 0.1)
log PFU/g, respectively, as compared with the 5.1 (6 0.1)
and 4.4 (6 0.1) log PFU/g of tissue observed in control-
treated IFN-a/bR KO mice (means of three mice per
group 6 SEM). These results show that the endogenous
IL-12 response in IFN-a/bR KO mice promotes the anti-
viral state of the host, but cannot substitute for endogenous
IFN-a/b in clearing virus expediently.
Discussion
These studies have characterized divergent innate path-
ways for promoting IFN-g responses during viral infec-
tions, with induction of high level IFN-a/b resulting in
conditions supporting one and acting to limit a potential al-
ternative IL-12 pathway. The experiments demonstrate (a)
an IFN-a/b pathway for IFN-g induction, and (b) IL-12
independence of the CD8 T cell responses of expansion
and IFN-g production, during LCMV infections. More-
over, they show that in the absence of endogenous IFN-a/b–
mediated functions, an IL-12 response is revealed and suffi-
cient to support induction of an IFN-g response, but not
peak protection. Despite delayed clearance of viral burdens,
the CD8 T cell expansion and IFN-g responses elicited in
the presence of the alternative IL-12 pathway are LCMV
specific because the expanded cells bind MHC tetramer
molecules complexed with the LCMV epitopes NP396-404
or GP33-41, and are stimulated to express IFN-g by viral
peptides. Although the substituted IL-12 acts to promote
IFN-g production, it does not appear to be required for ex-
pansion of virus-specific CD8 T cells. It is biologically signif-
icant, however, as viral titers increase if both pathways are
blocked. Thus, major contributions to adaptive CD8 T cell
responses are made by innate cytokines, predominantly IFN-
a/b, but alternatively IL-12, during viral infection.
These innate cytokine immunoregulatory pathways can
be contrasted to those characterized in response to nonviral
intracellular pathogens. Similar to the Th1 responses de-
fined under conditions of bacterial or parasitic stimuli (1,
3–9), LCMV infections induce IL-2 and IFN-g produc-
tion. However, in the other microbial infections, IL-12 is
the pivotal cytokine promoting Th1 responses (4–6, 8, 42).
The studies presented here conclusively demonstrate that,
in the complete absence of endogenous biologically active
IL-12 resulting from genetic mutation of the IL-12p35
subunit, LCMV-induced CD8 T cell expansion and IFN-g
expression proceed normally (Fig. 2, A–C). The lack of a
role for IL-12 in induction of T cell IFN-g expression con-
firms and extends an earlier report from this laboratory
demonstrating that neutralization of endogenous IL-12
function by treatment with antibodies directed against the
p40 chain does not inhibit LCMV induction of the T cell
responses in IFN-a/b competent mice (11). Moreover, it
is in agreement with the recent reports of lack of IL-12
effect on T cell IFN-g responses under the conditions of
treatments with antibody directed against the p40 chain
during influenza virus infections (12) and genetic mutation
of either the p35 or both the p35 and p40 molecules during
mouse hepatitis virus infections (14). Thus, there are indi-
cations in a variety of viral infections that T cell IFN-g re-
sponses are IL-12 independent.
In addition to showing the lack of importance for IL-12
in the presence of IFN-a/b functions, however, the studies
demonstrate an IFN-a/b role in supporting T cell IFN-g
production during viral infections. They define the exist-
ence of this pathway for the first time and characterize the
in vivo conditions under which it is important to the host.
The results are consistent with reported enhancing effects of
IFN-a/b for T cell IFN-g production under certain spe-
cific conditions in culture (27–29, 43). However, the culture
studies have been limited to examining the IFN-a roles for
modest effects in association with IL-12 (28, 43), CD4 T
cell subset IFN-g responses (27, 43), and/or dramatic effects
in association with the IFN-g–inducing factor (IGIF), some-
times called IL-18 (29). Ongoing studies in our laboratory
are evaluating a potential accessory role for IGIF under the
conditions of viral infections. The results presented here
contribute to defining the complete system by demonstrat-
ing that during viral infections IFN-a/b cytokines are dom-
inant for T cell IFN-g responses, mediate these effects in
the absence of IL-12, and act on CD8 T cell subsets.
The experiments also identify a secondary IL-12 response
absent in IFN-a/bR–competent but revealed in IFN-a/bR–
deficient mice (Figs. 6–8). The lack of IL-12 appearance in
the presence of IFN-a/b functions is consistent with the
known negative regulation of IL-12 by the cytokines (13).1324 IFN-a/b and IL-12 Pathways for Antiviral T Cell Responses
The alternative IL-12 response is beneficial to the host be-
cause it can substitute in promoting IFN-g production and
facilitates clearance of virus. However, it is apparently sub-
optimal because the conditions may fail to access the direct
antiviral effects of IFN-a/b and result in delayed viral
clearance. Thus, the responses elicited in the context of the
IFN-a/b–mediated effects are clearly better for defense
against this particular infectious agent, but the host can ac-
tivate substitute defense mechanisms. Although the two di-
vergent in vivo pathways to T cell IFN-g are clearly estab-
lished, it is not known if the IFN-a/b and IL-12 effects are
mediated directly or indirectly, or at the priming as com-
pared with the production phases. Experiments are under-
way examining these.
Remarkably, LCMV elicits particularly high circulating
levels of IFN-a/b, and under these conditions does not in-
duce IL-12 (10, 11, 13, 15). Immune responses to this infec-
tion may represent those on one end of a spectrum ranging
from exclusive dependence on IFN-a/b,  to codominant
regulation by IFN-a/b and IL-12, to exclusive dependence
on IL-12 for promoting IFN-g production. Our hypothesis
is that relative contributions would depend on presence or
absence and magnitude of induction levels. MCMV and in-
fluenza infections induce more mixed responses with detect-
able IL-12 (10–12, 44), and certain bacterial and parasitic in-
fections also may elicit both IL-12 and IFN-a/b expression
(6, 45, 46). Other intracellular bacteria may preferentially
elicit IL-12 responses (4). Direct comparison of infections
indicates that LCMV induces up to threefold higher levels
and sustains longer production periods of serum IFN-a/b
relative to MCMV (Cousens and Biron, unpublished re-
sults). The levels achieved during LCMV infection are suf-
ficient to mediate significant negative regulation of IL-12
(13). Thus, the picture emerging is that the immune system
is equipped to induce both IFN-a/b and IL-12 simulta-
neously; either will lead to conditions promoting IFN-g
production, but conditions of high IFN-a/b expression
make these cytokines dominant because they also are in-
hibiting the IL-12 response. As stated above, such condi-
tions appear to be beneficial because they access direct anti-
viral functions and are particularly conducive for induction
of protective responses. Moreover, as the dramatic T cell
responses to LCMV render the host more sensitive to
IL-12 toxicities (35, 36), they may additionally act to pro-
tect from detrimental immune responses.
Although effects of IFN-a/b on IFN-g production are
demonstrated, the results also indicate that total and virus-
specific CD8 T cell expansions are IFN-a/b independent
(Figs. 3 and 4), and that they occur even if both IFN-a/b
and IL-12 functions are blocked (data not shown). Thus,
other factors must be promoting CD8 T cell expansion
during LCMV infections. At least one adaptive cytokine,
IL-2, is apparently available to carry out this function. CM
levels of IL-2 are similar with cells from IFN-a/bR KO,
IL-12p35 KO, and WT mice, and only reduced by about
half with cells from mice blocked in both IFN-a/b and IL-
12 functions (data not shown). This cytokine is critical for
CD8 T cell expansion, and as a result of supporting T cell
proliferation, for peak T cell IFN-g responses (17, 21).
Thus, the innate cytokine IFN-a/b and/or IL-12 re-
sponses and the downstream consequences of these re-
sponses do not appear to be as important as IL-2 for T cell
expansion. In this regard, it has been suggested that IFN-
a/b may stimulate IL-15 production to promote prolifera-
tion of memory CD8 T cells during early viral infections
(47, 48). Our results suggest that an IFN-a/b induction of
IL-15 is not essential for virus-specific CD8 T cell prolifer-
ation during acute infections. However, it is interesting to
note that specificities of the expanded T cells are somewhat
skewed in the absence of IFN-a/b (Figs. 3 and 4). Thus,
there are additional unidentified IFN-a/b effects contrib-
uting to selection of the T cell repertoire activated against
infection.
The skewing of responses is observed at the level of rela-
tive proportions of CD8 T cells specifically binding tetra-
meric molecules complexed with NP396-404 or GP33-41
(Fig. 3). However, as the total numbers of cells binding one
or the other are similar in WT and IFN-a/bR KO mice,
the magnitude of the CD8 T cell proliferative responses is
IFN-a/b function independent. Nevertheless, overall re-
sponses to peptide stimulation for CD8 T cell expression of
cytoplasmic IFN-g expression (Fig. 4), and peptide stimu-
lation for IFN-g production (Table I) are reduced. More-
over, the total proportions of CD8 T cells primed to specif-
ically respond by expressing cytoplasmic IFN-g after ex
vivo stimulation with the LCMV peptides NP396-404 or
GP33-41 account for 90–95% of those sensitized to anti–
CD3 stimulation during infections of WT mice, but repre-
sent only 25–60% of those sensitized during infections of
IFN-a/bR KO mice (Fig. 4). Thus, anti–CD3 reveals cells
primed for T cell functions but failing to respond to the
NP396-404 or GP33-41 peptides. The populations stimu-
lated by anti–CD3, but not the tested LCMV peptides,
could represent T cells having receptors (a) recognizing
other LCMV epitopes, (b) nonspecifically activated, and/or
(c) altered in magnitudes of functions and/or requirements
for stimulation. There is evidence for the first two of these
under other conditions. Although NP396-404 and GP33-
41 represent the major immunodominant LCMV epitopes
detected in MHC H-2b mice (23–25, 39, 49, 50), other
minor epitopes have been identified (39). Despite promi-
nence of the virus-specific T cell responses, “bystander” ac-
tivation of memory phenotype T cells has been reported
during LCMV infections (47). However, the last possibility
seems most likely because CD8 T cells binding tetrameric
Db GP33-41 are dramatically expanded. Further experi-
ments are needed to conclusively distinguish between these
possibilities. Nevertheless, the studies clearly document ex-
pansion of a large proportion of cells specific for LCMV
epitopes and responding with IFN-g production.
LCMV is a relatively noncytopathic virus. In the absence
of T cell responses and/or under specific conditions of di-
minishing CTL responses, sometimes called “T cell ex-
haustion,” persistent LCMV infections can be established.
Although detectable CTL function is not induced during
LCMV infection in the absence of IFN-a/b (33; data not1325 Cousens et al.
shown), our results indicate that the conditions are suffi-
cient for resistance and eventual viral clearance (Fig. 8).
Thus, they are in contrast to the suggestion of others that,
in the absence of IFN-a/b–mediated regulation of viral
replication, LCMV-induced T cell exhaustion results from
an overwhelming viral burden (33, 34). Those investigators
have based their hypothesis on the lack of CTL activity
without enumerating CD8 T cell numbers. In our studies,
the two are dissociated; i.e., CD8 T cell expansion and
IFN-g production occur in the absence of apparent virus-
specific CTL function (data not shown). However, differ-
ent isolates of LCMV vary for spontaneous induction, in
immunocompetent mice, of T cell exhaustion as character-
ized by lack of CTL (51, 52) and persistent infection (51–
53), and it has been demonstrated that at least one of these
conditions also results in the lack of virus-specific CD8 T
cell expansion (54). Clearly, this is not the case under the
conditions of infection in our studies. However, it is in-
teresting to note that during chronic LCMV infections,
the specificity of CD8 T cell responses can vary such that
NP396-404–specific cells are deleted and functionally un-
responsive GP33-41–specific cells are maintained (55), and
that the skewing of specific T cells during infections of
IFNa/bR KO mice is in this direction; i.e., reduced
NP396-404 and increased GP33-41 specific cells (Fig. 3).
Thus, parameters in addition to the absence of IFN-a/b
functions must be required to extinguish defense and estab-
lish viral persistence, but protection mediated in the absence
of IFN-a/b functions may be shifting in dependence to-
wards T cell subsets sustained for longer periods of time
during infections and extended antigen stimulation.
In summary, data presented here define unique divergent
regulatory pathways promoting IFN-g responses to viral
infection, controlled by IFN-a/b or IL-12. They demon-
strate that the strong and protective CD8 T cell responses
of expansion and IFN-g production are induced though
IL-12–independent pathways during infections of immu-
nocompetent hosts. Moreover, the studies show that in the
absence of endogenous IFN-a/b, an IL-12 response can be
revealed and substitute conditions to promote IFN-g pro-
duction. Although not resulting in induction of the most
effective antiviral immune responses, the IL-12 substitution
is beneficial. Thus, the results define uniquely IFN-a/b–
controlled pathways for promoting peak defense during vi-
ral infections inducing these cytokines, and the plasticity of
immune responses in accessing an alternative pathway to
reach certain of the same goals.
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